Retraction
Combining PARP-1 Inhibition and Radiation in Ewing Sarcoma Results in Lethal DNA Damage
Paper Information
Record ID:
58520
Author(s):
Publication Date:
November 01, 2013
Retraction Date:
November 04, 2024
(1.0 year years ago)
Subjects:
Institutions:
- Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts
- Division of Radiation Effects, Korea Institute of Radiological and Medical Sciences, Seoul, Korea
- Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, D.C.
- Departments of Pharmacology and Cancer Biology and Radiation Oncology, Duke University Medical Center, Durham, North Carolina
- Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York
Countries:
Article Type:
Publisher:
American Association for Cancer Research
Open Access:
Yes
PubMed ID:
Retraction PubMed ID:
Retraction Details
Retraction Reasons:
Nature of Retraction:
Retraction
Retraction Notice:
10.1158/1535-7163.MCT-24-0802Citations (82)
82
Total Citations5
Post-Retraction(6.1%)
76
Pre-Retraction1
Same DayPost-Retraction Citation Analysis
1
Within 30 days
5
Within 1 year
0
After 2+ years
226
Days since retraction (latest)
Targeting the DNA Damage Response to enhance radiotherapy in soft tissue sarcomas
Bauke H.G. van Riet, Sanne Venneker, Judith V.M.G. Bovée et al. (5 authors)
Critical Reviews in Oncology/Hematology
Open Access
Published: Jun 2025
226 days after retraction
The Combination of <scp>PARP</scp> and Topoisomerase 1 Inhibitors Improves Radiation Therapy for Ewing Sarcoma
Xie Jia, Marcia Mellado-Lagarde, Kaley Blankenship et al. (15 authors)
Cancer Science
Open Access
Published: Mar 2025
127 days after retraction
Results of a phase Ib study of olaparib with concomitant radiotherapy in soft-tissue sarcoma: a French sarcoma group study
Paul Sargos, M.-P. Sunyach, Anne Ducassou et al. (12 authors)
Annals of Oncology
Open Access
Published: Jan 2025
1 citation
1 citation
58 days after retraction
Future Treatment in Sarcomas
Mohamad Farid, Jason Yongsheng Chan, Valerie Shiwen Yang et al. (5 authors)
Unknown Journal
Published: Jan 2025
58 days after retraction
Signaling pathways and targeted therapies in Ewing sarcoma
Jia Ke, Li Cao, Yihan Yu et al. (7 authors)
Pharmacology & Therapeutics
Open Access
Published: Nov 2024
2 citations
2 citations
26 days after retraction
Retraction: Combining PARP-1 Inhibition and Radiation in Ewing Sarcoma Results in Lethal DNA Damage
Hae‐June Lee, Changhwan Yoon, B. Schmidt et al. (9 authors)
Molecular Cancer Therapeutics
Published: Nov 2024
Same day as retraction
Therapeutic Targeting of DNA Repair Pathways in Pediatric Extracranial Solid Tumors: Current State and Implications for Immunotherapy
Sophia Zhao, Daniel Prior, Christine M. Heske et al. (4 authors)
Cancers
Open Access
Published: Apr 2024
2 citations
2 citations
193 days before retraction
Novel modifications of PARP inhibitor veliparib increase PARP1 binding to DNA breaks
Uday Kiran Velagapudi, Élise Rouleau-Turcotte, Ramya Billur et al. (8 authors)
Biochemical Journal
Open Access
Published: Feb 2024
4 citations
4 citations
259 days before retraction
Olaparib synergically exacerbates the radiation-induced intestinal apoptosis in mice
Sohee Jeong, Jeongmin Lee, Jun Hong Park et al. (9 authors)
Molecular & Cellular Toxicology
Published: Jan 2024
289 days before retraction
Unlocking epigenetics for precision treatment of Ewing’s sarcoma
Zhehao Fan, Shuangshuang Dong, Ning Wang et al. (6 authors)
Chinese Journal of Cancer Research
Open Access
Published: Jan 2024
308 days before retraction
The Chromatin Remodeler CHD4 Sustains Ewing Sarcoma Cell Survival by Controlling Global Chromatin Architecture
Joana G. Marques, Blaz Pavlovic, Quy A. Ngo et al. (10 authors)
Cancer Research
Published: Nov 2023
8 citations
8 citations
356 days before retraction
Poly(ADP-ribose) Polyremase-1 (PARP-1) Inhibition: A Promising Therapeutic Strategy for ETS-Expressing Tumours
Arnaud J. Legrand, Souhaila Choul‐li, Vincent Villeret et al. (4 authors)
International Journal of Molecular Sciences
Open Access
Published: Aug 2023
6 citations
6 citations
432 days before retraction
B-cell lymphoma 2 family members and sarcomas: a promising target in a heterogeneous disease
Rui Caetano Oliveira, João Martins Gama, José Casanova
Exploration of Targeted Anti-tumor Therapy
Open Access
Published: Aug 2023
1 citation
1 citation
438 days before retraction
Radiotherapy in bone sarcoma: the quest for better treatment option
Marie-Anaïs Locquet, Mehdi Brahmi, Jean‐Yves Blay et al. (4 authors)
BMC Cancer
Open Access
Published: Aug 2023
14 citations
14 citations
451 days before retraction
Novel insights into biomarkers of progression in Desmoid tumor
Baiqi Liu, Zefang Sun, Rui Zhou et al. (7 authors)
Frontiers in Oncology
Open Access
Published: Aug 2023
2 citations
2 citations
459 days before retraction
PARP-1: a critical regulator in radioprotection and radiotherapy-mechanisms, challenges, and therapeutic opportunities
Wenhao Li, Fei Wang, Gui-yuan Song et al. (6 authors)
Frontiers in Pharmacology
Open Access
Published: Jun 2023
18 citations
18 citations
517 days before retraction
Management of Unresectable Localized Pelvic Bone Sarcomas: Current Practice and Future Perspectives
Joaquim Soares do Brito, Miguel Esperança‐Martins, André Abrunhosa-Branquinho et al. (10 authors)
Cancers
Open Access
Published: May 2022
3 citations
3 citations
897 days before retraction
Is there a place for definitive radiotherapy in the treatment of unresectable soft-tissue sarcoma? A systematic review
Benoît Allignet, Marie‐Pierre Sunyach, Xavier Geets et al. (4 authors)
Acta Oncologica
Published: May 2022
8 citations
8 citations
904 days before retraction
BRCA1-Associated RING Domain-1 (BARD1) Loss and GBP1 Expression Enhance Sensitivity to DNA Damage in Ewing Sarcoma
Lisa M. Maurer, Jessica Daley, Elina Mukherjee et al. (16 authors)
Cancer Research Communications
Open Access
Published: Apr 2022
11 citations
11 citations
941 days before retraction
Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer
Marilyne Labrie, Joan S. Brugge, Gordon B. Mills et al. (4 authors)
Nature reviews. Cancer
Open Access
Published: Mar 2022
243 citations
243 citations
971 days before retraction
Stat1 confers sensitivity to radiation in cervical cancer cells by controlling Parp1 levels: a new perspective for Parp1 inhibition
Giuseppina Raspaglio, Marianna Buttarelli, Flavia Filippetti et al. (7 authors)
Cell Death and Disease
Open Access
Published: Oct 2021
15 citations
15 citations
1119 days before retraction
Lysine Methyltransferase Inhibitors Impair H4K20me2 and 53BP1 Foci in Response to DNA Damage in Sarcomas, a Synthetic Lethality Strategy
Ignacio Campillo‐Marcos, Eva Monte-Serrano, Elena Navarro-Carrasco et al. (5 authors)
Frontiers in Cell and Developmental Biology
Open Access
Published: Sep 2021
8 citations
8 citations
1158 days before retraction
Integrated Analysis of the Transcriptome Profile Reveals the Potential Roles Played by Long Noncoding RNAs in Immunotherapy for Sarcoma
Boran Pang, Yongqiang Hao
Frontiers in Oncology
Open Access
Published: Jun 2021
5 citations
5 citations
1242 days before retraction
Ewing sarcoma: investigational mono- and combination therapies in clinical trials
Jessica Gartrell, Carlos Rodríguez‐Galindo
Expert Opinion on Investigational Drugs
Published: Apr 2021
9 citations
9 citations
1296 days before retraction
Olaparib increases the therapeutic index of hemithoracic irradiation compared with hemithoracic irradiation alone in a mouse lung cancer model
Yanyan Jiang, Jennifer Martin, Maryam Alkadhimi et al. (13 authors)
British Journal of Cancer
Open Access
Published: Mar 2021
7 citations
7 citations
1326 days before retraction
Combination of talaporfin photodynamic therapy and Poly (ADP-Ribose) polymerase (PARP) inhibitor in gastric cancer
Mamoru Tanaka, Makiko Sasaki, Taketo Suzuki et al. (5 authors)
Biochemical and Biophysical Research Communications
Published: Jan 2021
15 citations
15 citations
1403 days before retraction
Eltrombopag inhibits the proliferation of Ewing sarcoma cells via iron chelation and impaired DNA replication
Torin Waters, Kelli L. Goss, Stacia L. Koppenhafer et al. (5 authors)
BMC Cancer
Open Access
Published: Nov 2020
11 citations
11 citations
1435 days before retraction
Inhibition of SIRT6 potentiates the anti-tumor effect of doxorubicin through suppression of the DNA damage repair pathway in osteosarcoma
Zhongkai Zhang, Sang Hoon Ha, Young Jae Moon et al. (14 authors)
Journal of Experimental & Clinical Cancer Research
Open Access
Published: Nov 2020
23 citations
23 citations
1448 days before retraction
Paper citing Combining PARP-1 Inhibition and Radiation in Ewing...
Unknown Authors
Unknown Journal
Published: Nov 2020
1448 days before retraction
Exploiting Replication Stress as a Novel Therapeutic Intervention
Jeffrey C. Martin, Tamara J. Hoegel, Miranda L. Lynch et al. (6 authors)
Molecular Cancer Research
Open Access
Published: Oct 2020
17 citations
17 citations
1491 days before retraction
Contemporary Approach to Therapy for Ewing Sarcoma
Steven G. DuBois, Uta Dirksen
Pediatric oncology
Published: Oct 2020
2 citations
2 citations
1495 days before retraction
PARP inhibition in Ewing sarcoma: impact of germline DNA damage repair defects and activation of immunoregulatory pathways
Lisa M. Maurer, Rosemarie E. Venier, Elina Mukherjee et al. (15 authors)
bioRxiv (Cold Spring Harbor Laboratory)
Open Access
Published: Sep 2020
1 citation
1 citation
1507 days before retraction
Current Status and Perspectives of Patient-Derived Models for Ewing’s Sarcoma
Tadashi Kondo
Cancers
Open Access
Published: Sep 2020
4 citations
4 citations
1522 days before retraction
Complete loss of ATM function augments replication catastrophe induced by ATR inhibition and gemcitabine in pancreatic cancer models
Charles R. Dunlop, Yann Wallez, Timothy Isaac Johnson et al. (9 authors)
British Journal of Cancer
Open Access
Published: Aug 2020
51 citations
51 citations
1555 days before retraction
Differential therapeutic effects of PARP and ATR inhibition combined with radiotherapy in the treatment of subcutaneous versus orthotopic lung tumour models
Vanessa Tran Chau, Winchygn Liu, Marine Gerbé de Thoré et al. (8 authors)
British Journal of Cancer
Open Access
Published: Jun 2020
17 citations
17 citations
1602 days before retraction
Harnessing the potential of multimodal radiotherapy in prostate cancer
Yiannis Philippou, Hanna Sjoberg, Alastair Lamb et al. (5 authors)
Nature Reviews Urology
Open Access
Published: May 2020
22 citations
22 citations
1648 days before retraction
Current Approaches for Personalized Therapy of Soft Tissue Sarcomas
Kirill Kirsanov, Ekaterina A. Lesovaya, Timur I. Fetisov et al. (6 authors)
Sarcoma
Open Access
Published: Apr 2020
7 citations
7 citations
1678 days before retraction
Breakthrough Technologies Reshape the Ewing Sarcoma Molecular Landscape
Carmen Salguero‐Aranda, Ana Teresa Amaral, Joaquín Olmedo-Pelayo et al. (5 authors)
Cells
Open Access
Published: Mar 2020
11 citations
11 citations
1684 days before retraction
Precision medicine in Ewing sarcoma: a translational point of view
Pablo Gargallo, A. De Juan, Yania Yáñez et al. (7 authors)
Clinical & Translational Oncology
Published: Feb 2020
17 citations
17 citations
1734 days before retraction
Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers
Jarosław Przybyciński, Magdalena Nalewajska, Małgorzata Marchelek‐Myśliwiec et al. (5 authors)
Expert Opinion on Therapeutic Targets
Published: Aug 2019
25 citations
25 citations
1914 days before retraction
Synthetic lethality between BRCA1 deficiency and poly(ADP-ribose) polymerase inhibition is modulated by processing of endogenous oxidative DNA damage
Sara Giovannini, Marie-Christine Weller, Simone Repmann et al. (5 authors)
Nucleic Acids Research
Open Access
Published: Jul 2019
33 citations
33 citations
1942 days before retraction
Exploiting Signaling Pathways and Immune Targets Beyond the Standard of Care for Ewing Sarcoma
Dana L. Casey, Tsung-Yi Lin, Nai‐Kong V. Cheung
Frontiers in Oncology
Open Access
Published: Jun 2019
27 citations
27 citations
1965 days before retraction
Faculty Opinions recommendation of Sensitizing Ewing sarcoma to chemo- and radiotherapy by inhibition of the DNA-repair enzymes DNA protein kinase (DNA-PK) and poly-ADP-ribose polymerase (PARP) 1/2.
Stephen L. Lessnick
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
Open Access
Published: Mar 2019
2048 days before retraction
Baicalein Suppresses Stem Cell-Like Characteristics in Radio- and Chemoresistant MDA-MB-231 Human Breast Cancer Cells through Up-Regulation of IFIT2
So Yae Koh, Jeong Yong Moon, Tatsuya Unno et al. (4 authors)
Nutrients
Open Access
Published: Mar 2019
71 citations
71 citations
2062 days before retraction
Combining PARP Inhibition, Radiation, and Immunotherapy: A Possible Strategy to Improve the Treatment of Cancer?
Mathieu Césaire, Juliette Thariat, Serge M. Candéias et al. (6 authors)
International Journal of Molecular Sciences
Open Access
Published: Nov 2018
73 citations
73 citations
2168 days before retraction
The Ewing Family of Tumors Relies on BCL-2 and BCL-XL to Escape PARP Inhibitor Toxicity
Daniel A.R. Heisey, Timothy L. Lochmann, Konstantinos V. Floros et al. (16 authors)
Clinical Cancer Research
Open Access
Published: Oct 2018
36 citations
36 citations
2205 days before retraction
Talazoparib Is a Potent Radiosensitizer in Small Cell Lung Cancer Cell Lines and Xenografts
J. Laird, Benjamin H. Lok, Jennifer Ma et al. (7 authors)
Clinical Cancer Research
Open Access
Published: Jun 2018
70 citations
70 citations
2323 days before retraction
The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma
Hye Jeong Park, Jun Sang Bae, Kyoung Min Kim et al. (13 authors)
Journal of Experimental & Clinical Cancer Research
Open Access
Published: May 2018
86 citations
86 citations
2359 days before retraction
Soft tissue sarcomas: new opportunity of treatment with PARP inhibitors?
Monica Mangoni, Mariangela Sottili, Giulia Salvatore et al. (15 authors)
La radiologia medica
Published: Mar 2018
17 citations
17 citations
2415 days before retraction
PARP-1 inhibition with or without ionizing radiation confers reactive oxygen species-mediated cytotoxicity preferentially to cancer cells with mutant TP53
Qi Liu, Liliana Gheorghiu, Michael Drumm et al. (15 authors)
Oncogene
Open Access
Published: Mar 2018
47 citations
47 citations
2436 days before retraction
Quick Stats
Total Citations:
82
Years Since Retraction:
1.0 year
Open Access:
Yes
Last Checked:
Jul 24, 2025